What happened

In response to reporting second-quarter earnings and announcing a common stock offering, shares of Evolent Health (NYSE:EVH), a fast-growing digital health technology company that offers a value-based payment platform, fell 16% as of 11:50 a.m. EDT on Tuesday.

So what

Here's a review of the headline numbers from the company's second quarter:

  • Adjusted revenue grew 90% to $107.3 million. This figure topped Wall Street's estimate by almost $3 million.
  • Adjusted net loss was $8.8 million, or $0.13 per share. This result matched what the pros were looking for.
  • The number of lives on the company's platform nearly doubled to 2.8 million.
  • Cash balance at quarter end was $124 million.

Here's a look at the guidance that was offered by management:

  • For the upcoming quarter, adjusted revenue is expected land between $103 million and $105 million. This range is in line with what analysts were expecting.
  • For the full year 2017, adjusted revenue is now projected to be in the range of $424 million to $428 million. This represents an increase over its former outlook of $415 million to $425 million.

While the earnings results and guidance were largely positive, the company also announced Tuesday that it is looking to raise up to $201.25 million through a common stock offering. This represents the company's fourth proposed common stock offering of the year. Given that Evolent just raised capital through stock offerings in June, May, and March, the news of yet another equity issuance is likely catching some investors off guard.

An arrow showing the downward trend of a chart on chalkboard with a business man in front of it.

Image source: Getty Images.

Now what

Even including Tuesday's plunge Evolent Health's investors are having a wonderful 2017. The company's stock has been on an absolute tear since January.

EVH Chart

EVH data by YCharts

Given that Evolent is still losing money and remains in investment mode, perhaps it isn't surprising to see that management wants to raise capital on favorable terms while it can. However, with so many equity offerings announced in such a short period of time, the company is also signaling to the markets its share price is richly valued.

On the other hand, Evolent's top-line growth remains extremely impressive, which shows that the healthcare community at large is rapidly flocking to the company's platform. With healthcare providers under a tremendous amount of pressure to lower their costs while simultaneously delivering higher quality care, it makes sense that more of them are looking to providers like Evolent for help. That makes this an interesting stock for growth-focused healthcare investors to get to know.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.